Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
– Phase 3 pivotal trials for I.V. CR845 expected to initiate during second quarter of 2015, following scheduled End-of-Phase 2 Meeting – – Reported positive top-line data from...
-
Pain experts to discuss latest kappa opioid agonist data and the future of pain management Company to present positive data from Phase 2 trial of I.V. CR845 during poster sessions...
-
SHELTON, Conn., March 19, 2015 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate...
-
SHELTON, Conn., March 13, 2015 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to...
-
SHELTON, Conn., Feb. 10, 2015 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to...
-
SHELTON, Conn., Feb. 2, 2015 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to...
-
SHELTON, Conn., Dec. 18, 2014 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to selectively...
-
I.V. CR845 observed to be safe, well tolerated, and to exhibit dose linear exposure in patients undergoing dialysis Effective itch reduction seen in subgroup of patients with uremic...
-
SHELTON, Conn., Dec. 2, 2014 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to...
-
All tested tablet strengths pharmacologically active, safe and well tolerated after single and multiple dose administration Establishes dosing range and regimen for Phase 2 trial design...